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Confirmation of a low HER2 positivity rate of
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Abstract
Background: Accurate assessment of the human epidermal growth factor receptor 2 (HER2) of invasive breast
cancer is essential to treatment decisions since the advent of targeted therapy with the humanized monoclonal
antibody trastuzumab and the dual tyrosine kinase inhibitor lapatinib. In the literature, the percentage of HER2-
overexpressed/amplified breast carcinomas range from 3% to 30%. The routinely assigned low rate of 9% of HER2-
overexpressed breast carcinomas alarmed one of our gynecologists who requested to confirm our HER2 test
results.
Methods: A small study of 83 patients with breast carcinoma was designed to reexamine the routinely assessed
HER2 status using immunohistochemistry and fluorescence in situ hybridization.
Results: The low rate of 9% of HER2-overexpressed/amplified breast tumors (DIN1C-3, invasive carcinoma) could be
confirmed. However, FISH revealed two false positive cases and one false negative case. Moreover a case with an
equivocal result in FISH was detected.
Conclusion: The HER2 positivity rate may be as low as 9%. The novel ASCO/CAP criteria for assessing
immunohistochemical results in HER 2 testing reduce the false positive rate of HER2. First-line testing with
immunohistochemistry may obscure false positive and false negative test results. In heterogeneous carcinomas
even fluorescence in situ hybridization may not succeed in a correct evaluation of HER2.
Background
The assessment of human epidermal growth factor
receptor 2 (HER2) in invasive breast cancer is manda-
tory for treatment decisions since the advent of targeted
therapy with the recombinant humanized IgG monoclo-
nal antibody trastuzumab (Herceptin®, Genentech, Inc.,
South San Francisco, CA, USA; Hoffmann-La Roche
Ltd., Basel, Switzerland) and the small molecule dual
HER1/HER2 tyrosine kinase inhibitor lapatinib (Tykerb,
GlaxoSmithKline, Philadelphia, PA, USA) [1]. The tras-
tuzumab antibody binds to the extracellular domain of
HER2, a transmembrane tyrosine kinase receptor, and
results in growth inhibition and apoptosis of tumor cells
overexpressing HER2 [2,3]. This overexpression of the
HER2 protein correlates with mRNA levels and the
amplification of the HER2 gene, allowing immunohisto-
chemical and in situ hybridization (ISH) assays for
determining the HER2 status of a cancer cell [4]. Scores
have been defined to evaluate the immunohistochemical
tests semiquantitatively (0-3+; Clinical trial assay Score,
HercepTest-Score) and ISH assays quantitatively (e.g.
Vysis-Ratio), which were slightly modified recently by
the American Society of Clinical Oncology and the Col-
lege of American Pathologists [5]. However, the best
method to assess the HER2 status remains controversial
[5]. According to Mass et al., only patients with HER2
gene amplification likely benefit from therapy with tras-
tuzumab, indicating that the preferred method for
selecting patients for antibody therapy is the assessment
of HER2 amplification by fluorescence in situ hybridiza-
tion (FISH) [6]. Presumably due to cost-effectiveness,
however, screening of all newly diagnosed breast carci-
nomas is mostly performed by immunohistochemistry
(IHC). In contrast to ISH techniques like FISH, IHC is
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any medium, provided the original work is properly cited.prone to false negative and false positive results due to
inappropriate tissue handling, and may even lead to
false positive results due to staining artifacts [7,8]. The
rate of HER2-overexpressed/amplified breast carcinomas
varies in the literature from 3% to 30%, but is mostly
given as 18-20% [4,5,9,10]. Therefore, this researcher
was alarmed by one of our gynecologists, who argued
that our HER2-positivity rate of breast carcinomas was
too low compared to published data, probably due to
incorrect test results. Therefore, this researcher designed
as m a l ls t u d yt or e e v a l u a t et h er o u t i n e l yd e t e r m i n e d
HER2 status using IHC, manual dual-color FISH (Path-
Vysion, Abbott molecular) and a technique to construct
a paraffin tissue microarray (PTMA) using paraffinized
needle biopsy specimens (PNBSs).
Methods
A total of 96 consecutive needle biopsy specimens from
88 different epithelial breast tumors, 8 non-invasive (duc-
tal intraepithelial neoplasia (DIN) 1C-3) and 80 invasive,
from 83 female patients were obtained from the slide and
paraffin block archive of the Institute of Pathology of the
University of Tuebingen, punched from January 2007 to
May 2007 in a center for breast carcinoma of a referring
hospital. DINs were also included in the PTMAs because
of the need to assess hormone receptor status (data not
shown). Following puncture tissue had been immediately
fixed in neutral buffered, alcohol stabilized formalin 4,5%
for between 6 and 18 hours, and routinely processed and
paraffin-embedded. Diagnoses were made, and hormone
and HER2 status evaluated.
A PTMA was constructed using PNBSs as described
elsewhere [11]. In short, a conventional bare paraffin
block was predrilled [12]. Of 96 PNBSs 84 PNBSs con-
tained an appropriate quantity of tumor, were punched
out of the paraffin blocks (donor blocks), placed in an
ordinary steel mold on a hot plate at 65°C to free the
PNBSs from the surrounding paraffin, picked up with a
spiky instrument, and manually transferred and inserted
into the holes of the predrilled PTMA (number of holes:
187; diameter of the holes: 1.4 mm; distance of the
holes: 0.3 mm; depth of the holes: 5 mm). The filled
PTMA was fully melted using a double-sided adhesive
tape and an x-ray film [13,14]. All further staining was
performed on 3-μm PTMA sections mounted on coated
slides and baked overnight at 37°C.
The rabbit polyclonal anti-HER2 antibody (Clone
A0485, DakoCytomation, Hamburg, Germany), which is
also used in the Dako HercepTest approved by the US
Food and Drug Administration (FDA) for the assess-
ment of the expression of the HER2 protein in breast
carcinomas, was applied in a standardized in-house
laboratory technique which was validated by the
German proficiency testing program for HER2 [4,15].
Using the PathVysion kit (Abbott Molecular, Abbott
Laboratories, Des Plaines, IL, USA), FISH was per-
formed according to the guidelines of the manufacturer.
Evaluation of the HER2 status was performed accord-
ing to manufacturer’s instructions (Abbott molecular,
Dako) and the ASCO/CAP guidelines, i.e. in IHC a four
graded system (0-3+) and in ISH a three graded system
(non amplified, equivocal, amplified) were utilized [5]
(Table 1). To determine the HER2 positivity rate using
FISH, the FDA-approved cut-off ratio (HER2 signals/
chromosome 17 signals) of 2.0 was used (Table 1).
Results
Routinely assessed HER2 status by IHC
Of a total of 88 breast tumors (DIN1C-3, invasive carci-
nomas) consecutively diagnosed in the first half of 2007,
73 tumors (83%) revealed no expression of HER2 (score
0) by our routine immunohistochemical assay, evaluated
according to the pre-ASCO/CAP guidelines. Five tumors
were scored as 1+ (6%), one tumor as 2+ (1%; low over-
expression), and eight tumors as 3+ (9%; high overex-
p r e s s i o n ;D I N :n=2 ;i n v a s i v ed u c t a lc a r c i n o m a :n=6 )
(Figure 1A). In one case (1%; DIN1C) the HER2 status
could not be determined due to loss of tumor material
in the deeper stained sections. Therefore, 87 breast
tumors were successfully scored for the immunohisto-
chemical HER2 status.
HER2 status using FISH
The HER2 status of these 87 tumors was reassessed by
FISH on either the PTMA, or on whole mount sections
of the PNBSs if the tumor could not be inserted suc-
cessfully into the PTMAs. Using FISH, eight tumors dis-
played amplification of the HER2 gene (DIN1C-3: n = 2;
invasive ductal carcinoma: n = 6), one tumor had an
equivocal score (HER2/chromosome 17 ratios: 1.6-2,1)
and one tumor showed polysomy 17 (HER2/chromo-
some 17 ratio: 1.1). 77 tumors displayed a diploid, non-
amplified genomic status. Thus, the HER2 positivity
rate, defined as HER2 amplified tumors/all tumors, was
9% (8/87; DIN1C-3, invasive carcinoma) or 8% on inva-
sive carcinomas alone(6/80).
Comparison of the routinely assessed
immunohistochemical HER2 status and FISH
Comparison of the routinely assessed immunohistochem-
ical HER2 status and FISH revealed that two invasive car-
cinomas diagnosed immunohistochemically as highly
overexpressed (score 3+) did not show amplification of the
HER2 gene by FISH, with the conclusion that these are
false positives (Table 2; cases 2 and 3; Figure 1B). More-
over, one tumor showed amplification by FISH, with
about 5-8 HER2 gene copies/tumor cell nucleus, although
it was originally diagnosed immunohistochemically as not
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f a l s en e g a t i v e( T a b l e2 ,c a s e4 ;F i g u r e1 C ) .O n et u m o r ,
which scored as 2+ by IHC, was proven to be amplified on
initial testing with FISH and confirmed in the study setting
(Table 2, case 1). Case 5, which proved to be equivocal by
FISH, was initially scored as 0/1+ by IHC (Table 2, case 5;
Figure 1D). One tumor with an immunohistochemical
score of 0/1+ showed a polysomy 17 by FISH (HER2/chro-
mosome 17 ratio: 1,1; Table 2, case 6).
Comparison of the routinely assessed
immunohistochemical HER2 status with the
immunohistochemical results in the study setting
No discrepancy was found between the routine and the
study assessment of the immunohistochemical HER2
status by this researcher using the ASCO/CAP criteria;
the false negative tumor described above was also not
detected in the study setting (Table 2, case 4).
Discussion
Alarmed by one of our gynecologists who argued that
our HER2 positivity rate of 9% of breast tumors
(DIN1C-3, invasive carcinoma) was too low in contrast
to most of the data presented in the literature (18-20%)
[5,9,10], this researcher designed a study to reassess the
routinely determined immunohistochemical HER2 status
and to compare the immunohistochemical results with
the gold standard dual color FISH, using PNBSs. The
PTMA technique was successfully applied to PNBSs.
The FISH test confirmed the low HER2 positivity rate of







Staining in < 10% of tumor cells
Negative/No staining
Staining in <10% of tumor cells
1+ Negative/Faint/barely perceptible
incomplete membrane staining
in >10% of tumor cells
Negative/Faint/barely perceptible
incomplete membrane staining
in >10% of tumor cells
2+ Weakly positive/Weak to moderate
complete membrane staining
in >10% of tumor cells
Equivocal/Weak to moderate
complete membrane staining
in >10% of tumor cells
3+ Strongly positive/Strong complete
membrane staining
in >10% of tumor cells
Positive/Strong complete
membrane staining








Positive/>= 2.0 Positive/> 2.2
HER2 human epidermal growth factor receptor 2; IHC immunohistochemistry; FISH fluorescence in situ hybridization; ASCO American Society of Clinical Oncology;
CAP College of American Pathologists; CEP17 chromosome enumeration probe 17 (probe for the centromer of chromosome 17)
Figure 1 Immunohistochemical HER2 status of selected cases. A Correctly identified immunohistochemical HER2 status scored as 3+
(positive) which proved to be amplified by FISH. B False positive immunohistochemical HER2 status originally scored as 3+ which proved to be
not amplified by FISH (Table 2, case 3). C False negative immunohistochemical HER2 status scored as 1+ which proved to be amplified by FISH
(Table 2, case 4). D Immunohistochemical HER2 status scored as 1+ which proved to be equivocal by FISH (Table 2, case 5). A-D Dako clone
A0485. ×20.
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Page 3 of 79%. A larger, ongoing trial in this laboratory with about
1000 breast carcinomas reveals a preliminary positivity
rate of 12%. In another study performed 5 years ago in
this laboratory, the HER2 positivity rate was 11% (17/
151 cases) (unpublished data). The discrepancy of this
data to the published HER2 positivity rates of up to 30%
is likely due to a different subset of patients, e.g. patients
with high-risk early-stage breast cancer and patients
with metastatic disease, in the older published studies
[5]. Newer studies approximate the same HER2 positiv-
ity rate as our findings. Yaziji describes 17% of breast
cancers being amplified in a study comprising 2913
cases [9]. Bilous et al. reported a HER2 3+ positivity
rate of 12% in a large study with 1536 breast carcino-
mas, and Chia et al. published a rate of 10.2% of HER2
positive breast cancers in their study cohort of 4444
invasive breast cancers [16,17]. Therefore, the incidence
of HER2 positive breast carcinomas was cut into half in
contrast to the early reports in the 1990’s.
Although the routinely detected immunohistochemical
HER2 positivity rate was confirmed by FISH, one false
negative and two false positive cases of routine IHC
resulted. The terms “false negative” and “false positive”
are based on the assumption that FISH testing with a
cut-off HER2/chromosome 17 ratio of 2.0 is the best
method of correctly identifying patients who are likely
to respond to trastuzumab therapy. The two false posi-
tive cases (Table 2, cases 2 and 3; Figure 1B) were
scored as 3+ by the first investigators due to a 10%
strong complete membranous expression of HER2 on
the tumor cells. The pre-ASCO/CAP guidelines, which
were still applied in the first months of 2007 in our
institute, determined the cut-off percentage for an
immunohistochemical 3+ score to be 10% of tumor cells
with a strong complete membranous expression of
HER2 (Table 1). If the ASCO/CAP guidelines with a
cut-off percentage of 30% had been applied, the two
false positive cases would not have been reported since
a FISH test would have been initiated. The two false
positive tumors would have been scored as 1+ by this
researcher; however the decision, whether 10% or less of
the tumor cells show a complete membrane staining for
HER2, appears to be sometimes very difficult. 25% (2/8)
of false positive (not-amplified) tumors is high; however,
Layfield et al. describe in their study that 22 cases out
of 79 immunohistochemically scored 3+ tumors were
also nonamplified by FISH (28%) [18].
The number of false negative cases in this study (1/77
(0/1+); 1%) (Table 2, case 4; Figure 1C) corresponds to
the published data. According to Sauter et al., 2-8% of
the carcinomas immunohistochemically scored as 0/1+
show amplification of the HER2 gene, and may be suita-
ble for trastuzumab therapy [8].
O n ec a s e( T a b l e2 ;c a s e5 ;F i g u r e1 D )p r o v e dt ob e
equivocal according to the ASCO/CAP guidelines with a
HER2/chromosome 17 ratio ranging from 1,6 to 2,1 in
different evaluations. A correct scoring of this tumor
seems to be impossible due to a somewhat heterogenous
tumor cell population with 2 to 7 HER2 signals per
tumor cell nucleus. Furthermore, the possibility of split
signals in FISH and the examination of cut nuclei in
paraffinized sections in contrast to cytological examina-
tions may contribute to this problem, and occasionally
makes it difficult to determine with certainty the num-
ber of HER2 gene copies per tumor cell nucleus. The
prevalence and importance of tumor heterogeneity is
controversial within the literature. In contrast to Press
et al., who described only 0.4% of heterogeneous tumors,
Pertschuk found up to 54% [19,20]. Brunelli et al.
reported on 13% of HER2 amplified tumors with focally
non-amplified tumor areas predominantly in low grade
amplified tumors [21]. Tubbs et al. described approxi-
mately 5% heterogeneous tumors, which is in the range
of our rate of 3%, as in two other cases in this study the
HER2 ratio varied between averages of 1.6 and 1.7 [22].
The large variation in the literature may be explained by
different definitions of heterogeneity. Can heterogeneity
be already diagnosed if some tumor cells show different
numbers of the HER2 gene, or is heterogeneity reserved
for tumors with a substantial portion of different cells e.
g .5 0 % ?I ti sl i k e l yt h a tt h e r ei saw i d er a n g eo ft u m o r s ,
especially in the low level amplification setting as
described by Brunelli et al., which display markedly dif-
ferent numbers in amplified tumor cells, leading to dif-
ferent ratios due to inhomogeneous distribution. Case 5
should be reported as “equivocal” to the clinicians
according to the ASCO/CAP guidelines. However, this
researcher has the experience that the clinical colleagues
are not content with the term “equivocal” because they
desire clear-cut statements concerning the therapy.
Probably, this case may be classified as “not amplified
and not suited for therapy with trastuzumab” because










Case 1 2+ 2+ A
Case 2 3+ ND NA
Case 3 3+ 0/1+ NA
Case 4 0/1+ 0/1+ A
Case 5 0/1+ 0/1+ E
Case 6 0/1+ ND PS
A amplified; E equivocal; FISH fluorescence in situ hybridization; IHC
immunohistochemistry; NA not amplified; ND not done; PNBSs paraffinized
needle biopsy specimens; PS polysomy chromosome 17; PTMA paraffin tissue
microarray.
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to FDA approved guidelines, and did not overexpress in
IHC tests performed.
In case 6 (Table 2), FISH revealed a polysomy 17 with
up to 8 HER2 gene and chromosome 17 signals per
tumor nucleus. The HER2/chromosome 17 ratio was
1.1, indicating a nonamplified status. Whether according
to Shah et al. a high polysomal 17-associated HER2
gene copy number is a significant contributing factor in
HER2 protein overexpression in unamplified invasive
breast carcinomas, and whether those cases should be
eligible candidates for treatment with trastuzumab, may
be still a matter of debate [23]. According to Bartlett et
al. and Watters et al., an increase in the HER2 gene due
to an increased chromosome 17 copy does not qualify
for amplification [24,25]. In addition to a ratio of 1.1,
trastuzumab therapy would not have been indicated in
our case due to an immunohistochemically determined
1+ score, indicating no overexpression of the HER2
gene.
Although this study comprises only a small number of
cases, the results reflect the ongoing dispute on the
favorable technique to prove the HER2 status of cancer
cells. Should IHC remain the first-line test and FISH
restricted to the immunohistochemical 2+ cases as it is
done in most laboratories? There may be several equally
valid answers to this question which depend on the goal
we want to achieve by the testing, and what degree of
uncertainty we will accept.
The variable error rate associated with IHC analysis of
paraffin-embedded tissues is well-recognized in the lit-
erature to show both false-negative and false-positive
results [26]. IHC is influenced by autolysis, fixation, and
epitope retrieval, and semi-quantitative scoring is prone
to inter- and intraobserver variability. Neither profi-
ciency testing nor on-slide controls may totally prevent
inaccurate results. If a certain level of false negative
cases is acceptable, then testing may continue. If the
goal is solely to avoid false positive immunohistochem-
ical testing in order to prevent unnecessary myocardial
toxicity and avoid high treatment cost, then all HER2
positive cases (scores 2+/3+) should be retested with
ISH before trastuzumab treatment, as already performed
in Belgium and Australia [27,28]. As described by Den-
dukuri et al, the strategy with the best cost-effectiveness
ratio involves screening all newly diagnosed cases of
breast cancer with IHC and confirming scores of 2+ or
3+ with FISH testing [29]. Also, Cuadros et Villegas are
in favour of testing 2+ and 3+ cases by ISH because of
IHC-ISH discordance rates among cases with IHC 2+
and IHC 3+ [30]. However, if the goal is to reduce false
positive and false negative rates to less than 1%, then
ISH techniques like FISH have to be utilized as the first-
line test. Especially FISH has proven to be the best
method of correctly identifying patients with metastatic
breast cancer who are likely to respond to trastuzumab
therapy [8]. Only rare cases respond to trastuzumab
therapy without proof of HER2 gene amplification. FISH
is both relatively independent of tissue fixation and
highly reproducible between laboratories. Failure of
FISH testing is reported to be 1-5%, with about 2% on
average [6,8]. This high FISH success rate is correlated
with analysis of DNA, which is the most stable macro-
molecule being evaluated, in contrast to analysis of RNA
and protein, as performed in IHC [8]. Despite high ana-
lysis costs for FISH testing, in contrast to IHC, Elkin et
a l .s h o w e dt h a ti ti sm o r ec o s t - e f f e c t i v et ou s eF I S H
a l o n ea st h ef i r s tl i n ea s s a y ,r a t h e rt h a nu s i n gF I S Ht o
confirm only weakly positive results or using the immu-
nohistochemical HercepTest alone [31]. A more cost-
effective way to determine HER2 status of all tumors by
ISH may be the use of PTMAs, either in the form of
PNBSs or tissue cores of the resection or mastectomy
specimens [26]. To prevent the time-consuming retrieval
of adequate tumor paraffin blocks from the archives,
PNBSs or tissue cores could be punched at the time of
routine handling and inserted in a consecutively filled
PTMA or a storing board over a certain period of time,
as published earlier [32]. Missing of heterogeneous
tumor components may be a disadvantage of the PTMA
technique, due to sampling errors. However, this may
also happen when the HER2 status is detected on the
small tumor volumes of the PNBSs. As demonstrated by
case 5 of our small study even FISH may not result in
an exact evaluation of the HER2 status if different
Vysis-Ratios are determined in different countings.
Despite our extensive efforts to prevent false positive
and negative testing, HER2 testing remains inefficient,
as only 12-34% of 3+ amplified breast carcinomas
respond to trastuzumab monotherapy [3]. So, until there
is agreement on the need for a gene array-based assay
to examine the signalling and effector pathways of the
HER2 receptor initially in each case, we will continue
testing with the gold standard FISH and other methods
like IHC which has to be called imperfect as already
pointed out by Dietel et al. [33].
Conclusions
T h eH E R 2p o s i t i v i t yr a t eo fb r e a s tt u m o r s( D I N 1 C - 3 ,
invasive carcinoma) may be as low as 9%. IHC as first-
line testing for HER2 may result in false positive and
false negative results. The novel ASCO/CAP criteria for
the immunohistochemical evaluation of the HER2 status
may prevent some false positive results. The most
robust method for studying HER2 status is ISH; how-
ever, correct ISH scoring may be impossible and mis-
leading in heterogeneous tumors with only a slight
increase in the HER2 copy number. If the paradigm of
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an ISH should be performed before treatment with tras-
tuzumab to detect false positive cases. Moreover, all
immunohistochemically screened cases should be
retested using the PTMA technology if false positive
and false negative cases are to be prevented. Until gene
array-based assays to evaluate the HER2 receptor path-
w a ya r ea v a i l a b l e ,t h eg o l ds tandard for assessment of
HER2 status in the future will remain ISH, e.g. FISH.
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